Lamivudina Aurobindo

Lamivudine, the active ingredient in Lamivudina Aurobindo, is a nucleoside reverse transcriptase inhibitor presented as an oral tablet for oral use. It treats human immunodeficiency virus (HIV) infection and chronic hepatitis B infection in adults and children as prescribed by a healthcare professional.

GNH USA supplies Lamivudina Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudine is an antiretroviral drug used in the management of viral infections that affect the immune system and liver.

- HIV infection: reduces viral load and helps restore immune function. - Chronic hepatitis B infection: suppresses HBV replication and lowers liver inflammation. - HIV‑1 infection (in combination therapy): forms part of highly active antiretroviral regimens to achieve durable viral suppression.

Lamivudine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, often transient. - Fatigue: general tiredness reported by some patients. - Diarrhoea: loose stools, usually self‑limiting.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially life‑threatening metabolic disturbance. - Severe liver injury: hepatic dysfunction requiring monitoring. - Pancreatitis: inflammation of the pancreas, may be severe. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions requiring immediate medical attention.

Patients should be monitored for specific safety concerns while receiving lamivudine.

- Monitor liver function: perform baseline and periodic liver enzyme tests. - Assess renal function: evaluate creatinine clearance before initiating therapy. - Screen for hepatitis B co‑infection: watch for reactivation risk. - Counsel on adherence: emphasize the importance of consistent dosing. - Store at ambient temperature: keep in the original container, protect from moisture.

Lamivudine can interact with several other medicines, requiring careful management.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis. - Stavudine: heightened peripheral neuropathy risk. - Ribavirin: potential for severe hemolytic anemia. - Alcohol: may exacerbate liver toxicity.

Moderate Interactions (Monitor Closely): - Efavirenz: possible reduction in lamivudine plasma levels. - Nevirapine: may increase liver enzyme elevations. - Tenofovir: monitor renal function when co‑administered.